About us
Neola Medical Management
Neola Medical’s management consists of a strong team of key people with both technical and medical expertise. The team is also complemented by an extensive network of specialist consultants.
Hanna Sjöström
External CEO since 2019.
Experience and education
Hanna Sjöström holds a Master’s in Business Administration and Technology Management from Lund University in Sweden and an Executive MBA from the Swedish Management Group. Sjöström is a highly commercially focused CEO with proven track record within Fast Moving Consumer Goods for +20 years from international roles at L’Oréal and the Coca-Cola Company in combination with Life Science CEO and executive roles at TePe and Neola Medical AB (publ). Hanna Sjöström is a certified and experienced board member of privately held AMB Industri AB, Reccan AB, Inscientia AB, Stratly AB and of Sweden’s largest industry organization for life sciences, SwedenBio.
Number of shares held in the company
233,640 shares, 200,000 warrants issued within the framework of the Incentive program 2021/2025A, 200,000 warrants issued within the framework of Incentive program 2023/2027A, 220 000 warrants within LTI 2022/2026.
David Folkesson
CFO since 2024.
Experience and education
David Folkesson has a Master’s degree in Economics and a Master’s degree in Business Administration and Management from Lunds University. He has over 15 years of experience in auditing, accounting, controlling, and financial advisory services in business-related roles at companies in various industries such as Deloitte and Pragati AB. Alongside his assignment at Neola Medical David has his own consultancy firm, D Folkesson Consulting AB and works as CFO at Dlaboratory Sweden AB and Watersprint AB (publ).
Number of shares held in the company
9,277 shares
Sara Bergsten
CTO since 2017.
Experience and education
Sara Bergsten has a PhD in physics from Lunds Tekniska Högskola within laser spectroscopy and optics with a focus on applications within medical diagnostics and therapy as well as a master’s degree in technical physics. Sara has previous experience in developing MedTech devices for optical diagnostics and therapy from two other smaller companies. She also has nine years experience from a larger industrial company within the aviation industry, ADB Safegate, where she worked with product development and global product owner. Sara is also a board member for Lund University Medical Laser Center, LUMLAC.
Number of shares held in the company
145,843 shares, 200,000 warrants issued within the framework of Incentive program 2023/2027A.
Magnus Johnsson
Director Quality Assurance & Regulatory Affairs since 2022.
Experience and education
Magnus Johnsson has a master’s degree in chemical engineering and a bachelor’s degree in systems analysis from Lund University. He has over 20 years of experience from working with quality control within the field of medical technology. Magnus last position was as Director of Quality at CellaVision AB.
Number of shares held in the company
2,400 shares, 100,000 warrants issued within the framework of Incentive program 2023/2027A.
Eva Bondesson
Clinical Director Quality since 2025.
Experience and education
Eva Bondesson holds a PhD from Lund University in advanced medical research with a focus on lung physiology, bioimaging and how the body functions in health and disease, and a master in pharmaceutical sciences from Uppsala University. She brings over 30 years of experience in medical technology and pharmaceutics, covering global clinical development, regulatory processes, and clinical study execution. Eva has held senior leadership positions at Active Biotech, Skåne University Hospital, Exini Diagnostics, and AstraZeneca, where she successfully led clinical development strategies supporting product approvals and launches across several therapeutic areas, with a particular focus on respiratory diseases.
Number of shares held in the company
0 shares
Invest in Neola Medical
At Neola Medical, our mission is to provide preterm born babies with a stronger and safer start in life. Through our innovative medical device, Neola®, we aim to advance neonatal intensive care by offering non-invasive, continuous, real-time lung monitoring, with the potential to support proactive care, reduce morbidity and improve quality of life for these vulnerable patients.
"We aim to detect lung complications immediately, giving healthcare professionals the tools they need to make life-saving decisions."
– Hanna Sjöström, CEO Neola Medical